Insulin and insulin resistance: Impact on blood pressure and cardiovascular disease

Medical Clinics of North America

Volumn 88, Issue 1, 2004, Pages 63-82

  Sowers, James R ^a,b   Frohlich, Edward D ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN B; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AEROBIC METABOLISM; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BLOOD VISCOSITY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIUM LESION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; PULSE PRESSURE; REGULATORY MECHANISM; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0842308149     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00128-7     Document Type: Review

References (162)

1. Sowers J.R., Sowers P.S., Peuler J.D. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med. 123:1994;647-652.
2. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and sympathetic adrenal system. N Engl J Med. 334:1996;374-381.
3. Nolan J.J., Ludvik B., Baloga J., Reuchart D., Olefsky J.M. Mechanisms of the kinetic defect in insulin action in obesity and NIDDM. Diabetes. 46:1997;494-500.
4. Sowers J.R. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension. 29:1997;691-699.
5. Sowers J.R. Effects of insulin and IGF-I on vascular smooth muscle glucose and cation metabolism. Diabetes. 45:(suppl 3):1996;S47-S51.
6. Ren J., Samson W.K., Sowers J.R. Insulin-like growth factor 1 as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol. 31:1999;2049-2061.
7. Sowers J.R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 158:1998;617-621.
8. Hunter S.J., Garvey T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction and glucose transport effector system. Am J Med. 5:1998;331-346.
9. Zeng G., Quon M. Insulin-stimulated production of nitric oxide is inhibited by Wortmannin: direct measurement in vascular endothelial cells that are also involved with glucose metabolism. J Clin Invest. 98:1996;894-898.
10. McFarlane S.I., Banerji M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 86:2001;713-718.
11. Ferrannini E., Buzzigoli C., Bonadonna R., et al. Insulin resistance in essential hypertension. N Engl J Med. 317:1987;350-357.
12. Shen D.C., Shieh S.M., Wu D.A., Reaven G.M. Resistance to insulin stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab. 66:1998;580-583.
13. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 342:1987;905-912.
14. Sowers J.R., Bakris G.L. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 342:2000;969-970.
15. Li D., Sweeney G., Wang Q., Klip A. Participation of PI3K and atypical PKC in Na+, K+-pump stimulation by IGF-1 in VSMC. Am J Physiol. 276:1999;H2109-H2116.
16. Zeng G., Nystrom F.H., Quon M.J. Roles for insulin receptor, PI3-kinase and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 101:2000;1539-1545.
17. Isenovic E.R., Divald A., Sowers J.R. Interactive effects of insulin-like growth factor-1 and β-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism. 52:2003;482-487.
18. Isenovic E.R., Muniyappa R., Sowers J.R. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. Journal of Biochemistry Biophysics Research Communication. 285:2001;954-958.
19. Isenovic E., Meng Y., Divald A., Milivojevic N., Sowers J.R. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells. Endocrine. 19:2002;287-291.
20. +-ATPase activity via PI3-K/Akt pathway in vascular smooth muscle cells. Int J Mol Med. 12:2003;1-12.
21. Folli F., Kahn R., Hansen H., et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest. 100:1997;2158-2169.
22. Fukuda N., Satoh C., Hu W.Y., et al. Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 19:2001;1651-1658.
23. Richey J.M., Ader M., Moore D., Bergman R.N. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol. 277:1999;E920-E926.
24. Rajagopalan S., Kurz S., Munzel T., et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contributions to alterations of vasomotor tone. J Clin Invest. 97:1996;1916-1923.
25. Berry C., Hamilton C.A., Brosnan M.J., et al. Investigations into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 101:2000;2206-2212.
26. Cifuentes M.E., Rey F.E., Carretero O.A., Pagano P. Upregulation of p67 (phox) and ggp91 (phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol. 279:2000;H2234-H2240.
27. Griendling K.K., Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. 91:2000;21-27.
28. Lassegue B., Sorescu D., Szocs K., et al. Novel gp91 (phox) homologues in vascular smooth muscle cells: nox 1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 88:2001;888-894.
29. Wang H.D., Xu S., Johns D.G., et al. Role of NADH oxidase in the vascular hypertrophic and oxidative stress responses to angiotensin II in mice. Circ Res. 88:2001;947-953.
30. Bayraktunan U., Draper N., Lang D., Shah A.M. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res. 38:1998;256-262.
31. Huerta M.G., Nadler J.L. Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr Diab Rep. 2:2002;396-402.
32. Guzik T.J., West N.E., Black E., et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 86:2000;E85-E90.
33. Görlack A., Brandes R.P., Nguryen K., et al. Agp91 phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 87:2000;26-32.
34. Mollnau H., Wendt M., Szocs K., et al. Effects of angiotensin infusion on the expression and functions of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 90:2002;E58-E65.
35. Lum H., Roebuck K.H. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol. 280:2001;C719-C741.
36. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 86:2000;494-501.
37. Touyz R.M., Quinn M.T., Pagano P., Schiffrin E. Expression of a functionally active gp91phox containing neutrophil-type N p(14) oxidase in smooth muscle cells from human resistant arteries. Circ Res. 90:2002;1205-1213.
38. Sowers J.R. Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 20:2002;346-348.
39. Pagano P.J., Clark J.K., Quinn M.T. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin 2. Proc Natl Acad Sci U S A. 94:1997;14438-14488.
40. 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 40:2002;521-527.
41. Montagnani M., Ravichandran L.V., Chen H., Esposito D.L., Quon M.J. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 16:2002;1931-1942.
42. Yamakawa T., Tanaka A., Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Hypertension. 35:2000;313-318.
43. Kitazawa T., Eto M., Woodsome T.P., Brautigan D.L. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem. 275:2000;9897-9900.
44. Kapur S., Bedard S., Marcotte B., Cote C.H., Marette A. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes. 46:1997;1691-1700.
45. Roy D., Perreault M., Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol Endocrinol Metab. 274:1998;E692-E699.
46. Reaven G.M., Chang H. Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in SHR and WKY rats. Am J Hypertens. 4:1991;34-38.
47. Standley P.R., Ram J.L., Sowers J.R. Insulin attenuation of vasopressin-induced calcium responses in arterial smooth muscle from Zucker rats. Endocrinology. 133:1993;1693-1699.
48. Alonso-Garcia M., Brands M.N., Hall J. Hypertension in obese Zucker rats: role of angiotensin II and adrenergic activity. Hypertension. 28:1996;1047-1054.
49. Jiang Z.Y., Lin Y.W., Clemont A., et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 104:1999;447-457.
50. Walsh M.F., Ali S., Sowers J.R. Vascular insulin/insulin-like growth factor-1 resistance in female obese Zucker rats. Metabolism. 50:2001;607-612.
51. Teisman A.C., Pinto Y.M., Brukema H., et al. Dissociation of blood pressure reduction from end-organ damage in TGR (Ren-2) transgenic hypertensive rats. J Hypertens. 16:1998;1759-1765.
52. Li P., Morris M., Ferrario C.M., et al. Cardiovascular endocrine, and body fluid electrolyte responses to salt loading in Ren-2 transgenic rats. Am J Physiol. 275:1998;130-137.
53. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 2:1979;131-141.
54. Sechi L.A., Melis A., Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism. 4:1992;1261-1266.
55. Grunfeld B., Balzareti H., Romo H., Gimenez M., Gutman R. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension. 23:1994;I12-I15.
56. Beatty O.L., Harper R., Sheridan B., Atkinson A.B., Bell P.M. Insulin resistance in offspring of hypertensive parents. BMJ. 3017:1993;92-96.
57. Taittonen L., Uhari M., Nuutinen M., Turtinen J., Pokka T., Akerblom H.K. Insulin and blood pressure among healthy children: cardiovascular risk in young Finns. Am J Hypertens. 9:1996;193-199.
58. Ducimentiere P., Eschwege E., Papoz L., Richard J.L., Claude J.R., Rosselin G. Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease. Diabetologia. 19:1980;205-210.
59. Fontbonne A., Charles M.A., Thibult N., Richard J.L., Claude J.R., Warnet J.M., et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia. 34:1991;356-361.
60. Després J.-P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957.
61. Agewall S., Fagerberg B., Attvall S., Wendelhag I., Urbanavicius V., Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke. 26:1995;956-960.
62. Salomaa V., Riley W., Kaark J.D., Nardo C., Folsom A.R. Non-insulin dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness index, the ARIC study. Circulation. 91:1995;1432-1443.
63. Suzuki M., Shinozaki K., Kanazawa A., Hara Y., Hattori Y., Tsushima M., et al. Insulin resistance as an independent risk for carotid wall thickening. Hypertension. 28:1996;593-598.
64. Shinozaki K., Naritomi H., Shimizu T., Suzuki M., Ikebuchi M., Sawada T., et al. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke. 27:1996;37-43.
65. Phillips G.B., Jing T.-Y., Resnick L.M., Barbagalla M., Laragh J.H., Sealey J.E. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. Am J Hypertens. 11:1993;699-702.
66. Haffner S.M., Karhapää P., Mykkänen L., Laasko M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 43:1994;212-219.
67. Tchernof A., Lamarchi B., Prud'homme A. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 19:1996;629-637.
68. Banerji M.A., Lebowitz J., Chaiken R.L., Gordon D., Kral J., Lebowitz H. Relationships of visceral adipose tissue and glucose disposal in independent of sex in black NIDDM subjects. Am J Physiol. 273:1997;E425-E432.
69. Liu Y., Ding L., Bush T.L., et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol. 154:2001;489-494.
70. Rimm E.B., Stampfer M.J., Giovannucci E., et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 141:1995;1117-1127.
71. Sowers J.R. Obesity and cardiovascular disease. Clin Chem. 44:1998;1821-1825.
72. Kim K.S., Owen W.L., Williams D., Adams-Campbell L.L. A comparison between BMI and Conicity index on predicting coronary heart disease: the Framingham Heart Study. Ann Epidemiol. 10:2000;424-431.
73. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 19:1999;972-978.
74. Festa A., D'Agostino R. Jr., Howard G., Mykkänen L. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:2000;42-47.
75. Brochu M., Starling R.D., Tchernof A., Matthews D.E., et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab. 85:2000;2378-2384.
76. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
77. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA. 289:2003;76-79.
78. Fung T.T., Rimm E.B., Spiegelman D., et al. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr. 73:2001;61-67.
79. Hak A.E., Coen D.A., Stehouwer M., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 19:1999;1986-1991.
80. Lakka H.M., Lakka T.A., Tuomilehto J., Salonen J.T. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J. 23:2002;706-713.
81. McTigue K.M., Garrett J.M., Popkin B.M. The natural history of the development of obesity in a cohort of young US adults between 1981 and 1998. Ann Intern Med. 136:2002;857-864.
82. Whitaker R.C. Understanding the complex journey to obesity in early adulthood. Am Intern Med. 136:2002;923-925.
83. Hall J.E. The kidney, hypertension and obesity. Hypertension. 41:2003;625-633.
84. McGill H.C. Jr., McMahan C.A., Herderick E.E., et al., for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 105:2002;2712-2718.
85. Williams D.E.M., Prevost A.T., Whichelow M.J., et al. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr. 83:2000;257-266.
86. Fung T.T., Willett W.C., Stampfer M.J., Manson J.E., Hu F.B. Dietary patterns and the risk of coronary heart disease in women. Arch Intern Med. 161:2001;1857-1862.
87. van Dam R.M., Willett W.C., Stampfer M.J., Hu F.B. Dietary patterns and risk for type 2 diabetes in US men. Ann Intern Med. 136:2002;201-209.
88. Sowers JR. Obesity as a cardiovascular disease factor. Am J Med, in press.
89. Stouthard J.M., Romijn J.A., Van der Poll T., et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol. 268:1995;E813-E819.
90. Papanicolau D.A., Wilder R.L., Manolagas S.C., Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:1998;127-137.
91. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 106:1999;506-512.
92. Pradhan A.D., Manson J.E., Rifai N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 286:2001;327-334.
93. Yudkin J.S., Kumari M., Munphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 148:2000;209-214.
94. Fernández-Real J.M., Vayreda M., Richard C., et al. Circulating interleukin 6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 86:2001;1154-1159.
95. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
96. Kern P.A., Saghizaden M., Ong J.M., et al. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:1995;2111-2119.
97. Mohamed-Ali V., Goodrick S., Rarwesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 82:1997;4196-4200.
98. Nilsson J., Jovinge S., Niemann A., Reneland R., et al. Relationship between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 18:1998;1199-1202.
99. Hotamisligil G.S. Mechanisms of TNF-α-induced insulin resistance. Exp Clin Endocrinol Diabetes. 107:1999;119-125.
100. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:2001;941-946.
101. Visser M., Bouter L.M., McQuillan G.M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 282:1999;2131-2135.
102. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
103. Steppan C.M., Brown E.J., Wright C.M., et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A. 98:2001;502-506.
104. El-Atat F, Aneja A, McFarlane S, Sowers JR. Obesity and hypertension. Recent Prog Horm Res, in press.
105. Mertens I., Van der Planken M., Corthouts B., et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res. 33:2001;602-607.
106. Freed M., Fuell D., Menci L., Heise M., Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. [abstract] Diabetologia. 43:2000;A267.
107. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 134:2001;61-71.
108. Katsuki A., Sumida Y., Murashima S., et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 83:1998;859-862.
109. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20:2000;1595-1599.
110. Combs T.P., Berg A.H., Obici T., et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 108:2002;1875-1881.
111. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20:2000;1595-1599.
112. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:2001;1930-1935.
113. Yamauchi T., Kamon J., Minakoshi Y., et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP activated protein kinase. Nat Med. 8:2002;1288-1295.
114. Stefan N., Vozarons B., Funahashi T., et al. Plasma adiponectin is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentrations precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 51:2002;1884-1888.
115. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 360:2002;57-58.
116. Yang W.-S., Lee W.-J., Funahashi T., et al. Weight reduction increases plasma levels of adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 86:2001;2815-2819.
117. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 105:2002;564-569.
118. Saghezadeh M., Ong J.M., Garvey W.T., et al. The expression of TNF-α by human muscle. J Clin Invest. 96:1996;1111-1116.
119. Yakda T., Orilani K., Takahashi T., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenetion and the functions of macrophages. Blood. 96:2000;1723-1732.
120. Schmidt M.I., Dunean B.B., Sharret A.B., et al. Markers of inflammation and predictor of diabetes mellitus in adults. (Atherosclerosis Risk in Communities Study): a cohort study. Lancet. 353:1999;1642-1652.
121. Festa A., D'Agostino R.J., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 51:2002;1131-1137.
122. Schneider D.J., Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor 1 by insulin and insulin-like growth hormone factor-1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A. 88:1991;9959-9969.
123. Chen Y.Q., Su M., Walia R.R., Hao Q., Vaughan D.E. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 273:1998;8225-8231.
124. Brown N.J., Kim K.S., Chen Y.Q. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 85:2000;336-344.
125. Hamsten A., William B., de Fair U., et al. Increased plasma levels of a rapid inhibitor of a tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
126. Hamsten A., Walldius B., de Faire U., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9.
127. Lupi F., Heom D.A., Bachmann F., et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 15:1995;1444-1445.
128. Winer N., Sowers J.R. Vascular compliance in diabetes. Curr Diab Rep. 3:2003;230-234.
129. McVeigh G., Brennan G., Hayes R., et al. Vascular abnormalities in non-insulin dependent diabetes mellitus identified by arterial waveform analysis. Am J Med. 95:1993;424-430.
130. Kass D.A., Shapiro A.P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycosylated end-produced cross-links. Circulation. 104:2001;1464-1470.
131. Gabriely I., Yang S.M., Cases J.A., et al. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol. 281:2001;R795-R802.
132. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension. 31:1998;409-414.
133. Correia M.L.G., Morgan D.A., Sivitz W.I., Mark A.L., Haynes W.G. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 37:2001;936-942.
134. Aizawa-Abe M., Ogawa Y., Masuzaki H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 105:2000;1243-1252.
135. Kennedy A., Gettys T.W., Watson P., Gananory G., Pan Q., Garvey W.T. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 82:1997;1293-1300.
136. Shiu W.H., Lee W.J., Chen Y.-T. High plasma leptin concentrations in hypertensive men but not in hypertensive women. J Hypertens. 17:1999;1289-1295.
137. Takizawa H., Ura N., Saitoh U.N., Wang L., et al. Gender difference in the relationships among hyperleptinemia, hyperinsulinemia, and hypertension. Clin Exp Hypertens. 24:2001;357-368.
138. Sharma A.M., Janke J., Garzelmak K., Engeli S., Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 40:2002;609-611.
139. McGarry J.D., Dobbins R.L. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 42:1999;128-138.
140. Danford E. Failure of adipocyte differentiation causes type 2 diabetes mellitus. Nat Genet. 26:2000;13.
141. Saint-Marc P., Kozala L.P., Aihaud G., Darimont C., Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology. 142:2001;487-492.
142. Janke J., Engeli S., Gorzelnisk K., Luft F.C., Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes. 51:2002;1699-1707.
143. Paolisso G., Tataronni P.I., Foley J.E., Bogardus C., Howard B.V., Rasrussin E. A high concentration of fasting plasma non-esterified fatty acids is risk factor for the development of NIDDM. Diabetologia. 38:1995;1213-1217.
144. Sowers J.R., Epstein M., Frolich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 37:2001;1053-1059.
145. Sowers J.R., Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension. 40:2002;781-788.
146. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 with lifestyle intervention or Metformin. N Engl J Med. 346:2002;393-403.
147. Sowers J.R., Lester M.A. Diabetes and cardiovascular disease. Diabetes Care. 22:(suppl 3):1999;C14-C20.
148. The Diabetes Prevention Program (DPP). Description of lifestyle intervention. Diabetes Care. 25:2002;2165-2171.
149. Bakris G., Palant C.E., Walsh M.F., Sowers J.R. Analogy between endothelial mesangial cell and endothelial vascular smooth muscle interactions: role of growth factors and mechanotransduction. Sowers J.R. Contemporary endocrinology: endocrinology of the vasculature. 1996;341-355 Humana Press, Totowa, NJ.
150. Keane W.F. Proteinuria: its clinical importance and its role in progressive renal disease. Am J Kidney Dis. 35:2001;97-105.
151. Remuzzi G., Schuppate A., Ruggenente P. Clinical practice: nephropathy in patients with type 2 diabetes. N Engl J Med. 346:2002;1145-1157.
152. Forsblom C.M., Eriksson J.G., Ekstrand A.V., et al. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia. 38:1995;363-369.
153. Mykkanen L., Haffner S.M., Kuusisto J., Pyorala K., Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes. 43:1994;552-557.
154. Morse S.P., Ellis S.G., Gurm H.S., et al. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J. 39:2000;939-944.
155. Miettinen H., Haffner S.M., Lehto S., et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin dependent diabetic subjects. Stroke. 27:1996;2033-2039.
156. Deckert T., Feldt-Rasmussin B., Borch-Johnson Y., et al. Albuminuria reflects widespread vascular damage: the steno-hypothesis. Diabetologia. 32:1989;219-226.
157. Agewall S., Wikstarnd J., Ljungman S., Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with or without diabetes mellitus. Am J Cardiol. 80:1997;164-196.
158. Shiuchi T., Cui T.X., Wu L., et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension. 40:2002;329-334.
159. Kotchen T.A., Zhang H.Y., Covelli M., Blehschmidt N. Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats. Am J Physiol. 261:1991;E692-E697.
160. Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 2:1979;154-160.
161. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359.
162. Rothenbacher D., Hoffmeister A., Brenner H., Koenig W. Physical activity, coronary heart disease, and inflammatory response. Arch Intern Med. 163:2003;1200-1205.